Le Lézard
Classified in: Health
Subject: PER

RevHealth Appoints Stacey Crowley To Lead Agency Growth


MORRISTOWN, N.J., May 2, 2024 /PRNewswire/ -- RevHealth, a full-service independent pharmaceutical marketing and communications agency, has appointed Stacey Crowley to the newly created role of Senior Vice President, Growth. The announcement continues the agency's positive momentum as it solidifies its strong leadership bench.

Before joining RevHealth, Crowley spent 17 years at McCann Torre Lazur. Beyond her tenure in account management rising to Vice President, Management Supervisor, Stacey took on new roles for the organization including driving growth for the creative practice as a creative services director and building digital competency across the agency as a senior digital account manager. She joined RevHealth in 2020 to lead key client accounts including US WorldMeds and Recordati Rare Diseases.

"Stacey has a deep understanding of our clients' marketing challenges, and her leadership will be pivotal for the agency as we continue to grow our portfolio of AOR relationships," said Chief Executive Officer Ben Beckley. Crowley will lead marketing as part of the company's new brand and enhanced full-service value proposition, launched in January 2024.

Crowley's appointment is the latest in a series of strategic hires and appointments since RevHealth's 2022 acquisition by WindRose Health Investors. Earlier this year the agency welcomed Ben Beckley as Chief Executive Officer, along with Marcia Goddard as Chief Creative Officer and Deb Jamer as Chief Operating Officer.

About RevHealth
Based in Morristown, NJ, RevHealth creates brand experiences that inspire change. The award-winning full-service independent pharmaceutical marketing and communications agency is anchored in a deep understanding of science throughout lifecycle marketing and has delivered revolutionary omnichannel solutions for pharma and biotech brands for almost 20 years. For more information, please visit www.revhealth.com.

Contact:
Stacey Crowley
[email protected]

SOURCE RevHealth


These press releases may also interest you

at 04:45
ERS Genomics Limited (?ERS'), the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants IRBM access to ERS' CRISPR/Cas9 patent portfolio....

at 03:15
Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on haemostatic medical device technologies, today announced it has entered into a distribution agreement for its revolutionary haemostatic gel, VETIGEL®, to be sold directly...

at 02:30
Ahead of International Tea Day - 21st May 2024  - and with summer inspiring more of us to get off the sofa to be active, a 2024 real-world research study1 reviewed by the tea science experts at the Tea Advisory Panel ? www.teaadvisorypanel.com -...

at 02:30
TreeFrog Therapeutics will participate for the first time at the IAPRD, to present data from their Parkinson's disease cell therapy program, which has demonstrated excellent results with full motor recovery at 16 weeks in preclinical studies.[1]...

at 02:20
Vicore Pharma Holding (STO:VICO)Buloxibutid improved lung function-measured by FVC-by over 200 mL from baseline at 36 weeks of treatment.The therapy was safe and well tolerated with no treatment-related serious adverse events.Biomarker analysis...

at 02:07
GC Biopharma (006280. KS) and Novel Pharma announced that its jointly developed MPS IIIA 'GC1130A' treatment has received FDA IND approval....



News published on and distributed by: